Adomeglivant

Confirm delete?

Adomeglivant

Zoom

Cat No: 29668

Biochemicals - Receptor Pharmacology

Adomeglivant is an allosteric antagonist of the glucagon receptor.{47796,47797} It inhibits glucagon-induced increases in cAMP levels in HEK293 cells expressing the rat glucagon or GLP-1 receptors (IC50s = 1.8 and 1.2 µM, respectively) but has no effe...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

N-[4-[(1S)-1-[[4?-(1,1-dimethylethyl)-2,6-dimethyl[1,1?-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]-?-alanine

Correlated keywords:

872260-20-3 LY 2409021 HEK 293 GLP1

Product Overview:
Adomeglivant is an allosteric antagonist of the glucagon receptor.{47796,47797} It inhibits glucagon-induced increases in cAMP levels in HEK293 cells expressing the rat glucagon or GLP-1 receptors (IC50s = 1.8 and 1.2 µM, respectively) but has no effect on cAMP levels when used alone.{47797} Adomeglivant also inhibits increases in cAMP levels induced by GLP-1 or exendin-4 (Item No. 11096) in HEK293 cells expressing the GLP-1 receptor (IC50s = 7 and 12 µM, respectively). It decreases glucose-stimulated insulin secretion when used at a concentration of 1 µM in combination with the GLP-1 receptor antagonist exendin (9-39) in isolated human islets but not glucose-stimulated glucagon secretion when used alone or in combination with exendin (9-39) in isolated mouse islets.{47798}

Size	1 mg
Shipping	dry ice
CAS Number	1488363-78-5
Molecular Formula	C₃₂H₃₆F₃NO₄
SMILES	CC(C)(C)C1=CC=C(C2=C(C)C=C(O[C@H](C3=CC=C(C(NCCC(O)=O)=O)C=C3)CCC(F)(F)F)C=C2C)C=C1
Molecular Weight	555,6
Formulation	A solid
Purity	≥98%
Custom Code	2924.29
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.